Yahoo Finance5d
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
TOKYO & BASKING RIDGE, N.J., January 13, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company ... of advanced solid tumors including non-small cell lung, breast, urothelial, ovarian, biliary tract ...
Morningstar6d
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1 (TA-MUC1) antibody ...
Yahoo Finance5d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo has been particularly active in this field, and the company’s collaborations including the one with AstraZeneca, have led to the development of successful drugs like Enhertu ...
Pharmabiz4d
Daiichi Sankyo to pay $132.5 million to acquire IP rights for anti-TAMUC1 antibody in DS-3939 from Glycotope
Daiichi Sankyo ... using Daiichi Sankyo’s proprietary DXd ADC technology. DS-3939 is currently being evaluated in a phase 1/2 clinical trial in patients with several types of advanced solid tumours ...
Joplin Globe6d
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
“Treating advanced EGFR-mutated non-small cell lung cancer ... Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU ® in March 2019 ...
Business Insider6d
AstraZeneca, Daiichi Sankyo datopotamab deruxtecan BLA granted priority review
Daiichi Sankyo and AstraZeneca’s (AZN ... or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer who have received prior systemic therapies, including an EGFR-directed ...
Morningstar6d
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Daiichi Sankyo.“If approved, datopotamab deruxtecan could become the first TROP2 directed antibody drug conjugate for lung cancer, providing a promising option for patients.” “Acquired ...
Nasdaq6d
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
11 There is currently no TROP2 directed ADC approved for the treatment of lung cancer ... About the ADC Portfolio of Daiichi Sankyo The Daiichi Sankyo ADC portfolio consists of seven ADCs in ...
Yahoo Finance6d
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug ...
pharmaphorum3d
WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer
On safety, there was a case of interstitial lung disease (ILD), a side effect that has been seen with other ADCs using Daiichi Sankyo's deruxtecan payload, like AstraZeneca's Enhertu (trastuzumab ...
The Pharma Letter4d
Daiichi Sankyo pays $132 million for Glycotope’s gatipotuzumab
DS-3939 is currently being evaluated in a Phase I/II clinical trial in patients with several types of advanced solid tumors including non-small cell lung, breast, urothelial, ovarian, biliary tract ...